EPO Upholds Teva’s Copaxone 40mg Dosing-Regimen Patent

 
• By Aidan Fry
  
TevaWebsite
Teva has seen a dosage-regimen patent for Copaxone upheld by the EPO, but may find national courts have other ideas • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin